The Medicines Co (MDCO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

8 SYLVAN WAY PARSIPPANY, NJ 07054

Operates as a pharmaceutical company that specializes in acute care hospital products. Its first acute care hospital product, Angiomax (bivalirudin), is a direct thrombin inhibitor used as an anticoagulant in patients undergoing coronary angioplasty.

Data as of 2019-12-02 10:28:29 -0500
Market Cap6.73 Billion Shares Outstanding79.933 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-3.107
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low84.3 / 16.69 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from MDCO instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding MDCO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MDCO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MEANWELL CLIVE CHIEF INNOVATION OFFICER

  • Officer
  • Director
0 2020-01-06 0

RODIN STEPHEN M EVP AND GENERAL COUNSEL

  • Officer
0 2020-01-06 0

DENNER ALEXANDER J

  • Director
0 2020-01-06 0

PANAYIOTOPOULOS PARIS

  • Director
0 2020-01-06 0

GERMANO GENO J

  • Director
0 2020-01-06 0

SCHLESINGER SARAH J.

  • Director
0 2020-01-06 0

VISIOLI CHRISTOPHER CHIEF FINANCIAL OFFICER

  • Officer
0 2020-01-06 0

TIMNEY MARK CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-01-06 0

WIJNGAARD PETER CHIEF DEVELOPMENT OFFICER

  • Officer
0 2020-01-06 0

KELLY JOHN C.

  • Director
0 2019-09-26 0

COX CHRISTOPHER T EVP & CHIEF CORP. DEV. OFFICER

  • Officer
392,942 2019-03-04 0

ESHELMAN FREDRIC N EXECUTIVE CHAIRMAN

  • Officer
  • Director
2,076,686 2018-05-31 0

SPIGELMAN MELVIN K

  • Director
53,133 2018-05-25 0

KESSLER ARMIN M

  • Director
138,493 2018-05-10 0

WYATT ELIZABETH H S

  • Director
60,633 2018-03-22 0

CROUSE WILLIAM

  • Director
53,133 2018-03-21 0

O'CONNOR WILLIAM BERNARD CHIEF FINANCIAL OFFICER

  • Officer
21,882 2018-03-02 0

FRAZIER JEFF EVP, CHIEF HUMAN STRATEGY

  • Officer
34,350 2018-03-02 0

HUGIN ROBERT J

  • Director
163,431 2017-11-09 0

SHIGETA HIROAKI

  • Director
26,784 2017-05-25 0

KINGSLEY STUART A PRESIDENT AND COO

  • Officer
11,386 2017-03-01 0

SAVAGE ROBERT G.

  • Director
31,146 2016-05-26 0

SBLENDORIO GLENN PRESIDENT & CFO

  • Officer
  • Director
99,805 2015-09-03 0

FURSE BRENT EVP, CHIEF CUSTOMER OFFICER

  • Officer
41,044 2014-08-29 0

KUSIAK VICTORIA EVP, CHIEF INTEGRITY OFFICER

  • Officer
3,519 2014-03-03 0

HEIMAN CORNELIS EVP, CHIEF INNOVATION OFFICER

  • Officer
11,457 2014-03-03 0

ANTINORI PAUL MICHAEL SR. VP & GENERAL COUNSEL

  • Officer
No longer subject to file 2014-02-25 0

ROHRBACKER LESLIE C VP, CHIEF HUMAN STRATEGY OFFIC

  • Officer
13,628 2012-02-21 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD PARTNERS, LP

DEERFIELD MANAGEMENT CO /NY

DEERFIELD INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUP
No longer subject to file 2011-04-04 0

JOHNSON T SCOTT

  • Director
No longer subject to file 2009-07-21 0

WATSON PACICCO KELLI SENIOR VICE PRESIDENT

  • Officer
2,211 2009-02-20 0

KELLEY JOHN P PRESIDENT AND COO

  • Officer
  • Director
55,615 2009-02-20 0

NEWBERRY CATHARINE S SENIOR VICE PRESIDENT

  • Officer
No longer subject to file 2009-01-26 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund MDCO -1233.0 shares, $-104731.02 2019-12-31 N-PORT
American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund MDCO -8687.0 shares, $-434350.0 2019-09-30 N-PORT
American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund MDCO -26680.0 shares, $-1334000.0 2019-09-30 N-PORT
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund MDCO -257.0 shares, $-12850.0 2019-09-30 N-PORT

Elevate your investments